Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 225 recruiting now early-phase tilt #2 of 28,707 conditions

Healthy: early-phase trial registry

225 of 1,096 indexed Healthy trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2 of 28,707 conditions by registered trial count.

1,096 US clinical trials · 225 currently recruiting · #2 of 28,707 conditions by registered trial count

Healthy: 1,096 US clinical trials tracked, 225 recruiting.

Healthy is the subject of 1,096 registered US clinical trials on ClinicalTrials.gov, 225 of them currently open to new participants. 43 are in Phase 3-4 (later-stage) and 546 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 55 of these trials.

Enrollment posture brief

Registry condition healthy

OPEN 225 | RECR 21% | LATE 43 | EARLY 546 | RANK #2 | SPON 55

Nearest open-share peer: Psoriasis (20% recruiting · 127 trials)

Prostate Cancer36.7%Depression35.7%Breast Cancer33.8%Obesity28.9%Healthy (this)21%
Open-enrollment share among volume-matched conditions near Healthy

Healthy lists 225 open slots (21% of 1,096 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Healthy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Healthy is recruiting below its size-band peers.

    225 of 1,096 indexed trials (20.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Healthy trials is spread across many organizations.

    Eli Lilly and Company accounts for 55 of 1,096 trials (5%). 429 distinct sponsors appear on at least one study for this condition label.

  3. Most Healthy trials plan to enrol fewer than 100 people.

    Median target enrolment is 40 among the 1,091 trials that report a genuine target (sentinel values excluded). 851 of those (78%) plan for fewer than 100 participants.

  4. Healthy research is mostly interventional.

    905 interventional and 191 observational studies make up this index (82.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1518Phase 228Phase 311Phase 432

Open and recent trials

1,096 total, page 21 of 22

COMPLETED Phase 1 13 participants

The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males

BeiGene

NCT04470908

COMPLETED Phase 1 13 participants

Persisting Effects of Psilocybin

Johns Hopkins University

NCT02971605

COMPLETED Phase 1 13 participants

A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects

Hutchison Medipharma Limited

NCT04372407

COMPLETED NA 13 participants

Infectivity of Norovirus in Groundwater-Human Challenge Study

Emory University

NCT00313404

COMPLETED 13 participants

Neuroimaging of St. John's Wort-Induced Changes of Serotonin Metabolism in Normal Subjects

National Institute of Mental Health (NIMH)

NCT00001919

COMPLETED NA 13 participants

Metaplasticity Experimental Design and Comparison of Motor Outcome Measure Sensitivity to Change

University of New Mexi

NCT03304262

COMPLETED NA 12 participants

Impact of a High-fat Meal on Assessment of Clopidogrel-induced Platelet Inhibition in Healthy Subjects

University of Nebraska

NCT01307657

COMPLETED NA 12 participants

BMS Reverse Cholesterol Transport (RCT) Study

University of Pennsylvania

NCT01031862

COMPLETED Phase 1 12 participants

A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants

Janssen Research & Development

NCT03593954

COMPLETED NA 12 participants

Bioavailability of Avenanthramide-Enriched Oats in Healthy Older Adults

Tufts University

NCT01055717

COMPLETED Phase 1 12 participants

A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant

Pfizer

NCT06275841

COMPLETED Phase 1 12 participants

A Study of Inhalation of 20,000 EU CCRE and Mucociliary Clearance (MCC) in Otherwise Healthy Individuals Who Are Current Cigarette Smokers

University of North Carolina, Chapel Hill

NCT00924768

COMPLETED Phase 1 12 participants

Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters

Pfizer

NCT01819922

COMPLETED NA 12 participants

Oral Liposomal Glutathione Supplementation in Healthy Subjects

Milton S. Hershey Medical Center

NCT02278822

COMPLETED Phase 1 12 participants

A Study to Learn If the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine Ibuzatrelvir in Healthy Adults

Pfizer

NCT06646042

COMPLETED Phase 1 12 participants

A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants

Eli Lilly and Company

NCT04194892

COMPLETED Phase 1 12 participants

A Safety Study of ARRY-300 in Healthy Subjects

Array Biopharma, now a wholly owned subsidiary of Pfizer

NCT00828165

COMPLETED NA 12 participants

SpO2 Accuracy of Noninvasive Pulse Oximeter Sensor

Stryker Sustainability Solutions

NCT05141500

COMPLETED Phase 1 12 participants

Relative Bioavailability Study of IX-01 Caplet Versus Aqueous Dispersion and Food Effect of the Caplet in Healthy Males

Ixchelsis Limited

NCT02962531

COMPLETED NA 12 participants

The Effects of Ginger Supplementation on Inflammation in Exercising Individuals

Loma Linda University

NCT03219463

COMPLETED Phase 1 12 participants

A Study of Sustained-Release Liothyronine Sodium (T3) in Healthy Subjects

Ipe

NCT01581463

COMPLETED Phase 3 12 participants

The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans

Adrian Vella

NCT04461015

COMPLETED NA 12 participants

A Study to Determine the Inter/Intra Observer and Intra-subject Variability of Whole Blood Clotting Time Measurements

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals

NCT02205827

COMPLETED Phase 1 12 participants

A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.

Pfizer

NCT04111614

COMPLETED Phase 1 12 participants

Evaluation of the Ocular Safety of Calcium Formate in Normal, Healthy Female Subjects

University of Wisconsin, Madison

NCT00204893

COMPLETED Phase 1 12 participants

Nitrite Infusion in Healthy Volunteers

National Institute of Neurological Disorders and Stroke (NINDS)

NCT00103025

COMPLETED Phase 1 12 participants

A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants

Janssen Research & Development

NCT03564379

COMPLETED NA 12 participants

The Potential for Pomegranate Juice to Ameliorate Endothelial Dysfunction

Janet Novotny

NCT01748617

COMPLETED NA 12 participants

A Study to Validate Treadmill Parameters

Mayo Clinic

NCT05333263

COMPLETED Phase 1 12 participants

Comparison of Two Formulations of Proellex for Oral Administration

Repros Therapeutics

NCT02141061

COMPLETED Phase 1 12 participants

Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects

Cara Therapeutics

NCT03947970

COMPLETED Phase 1 12 participants

Pharmacokinetic Study of Synera in Healthy Volunteers

ZARS Pharma

NCT01602757

COMPLETED Phase 1 12 participants

A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid

Abbott

NCT01009216

COMPLETED Phase 1 12 participants

Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants

Cerevel Therapeutics

NCT05123079

COMPLETED Phase 1 11 participants

A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%

Aciex Therapeutics

NCT02173249

COMPLETED Phase 1 11 participants

Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules

Pfizer's Upjohn has merged with Mylan to form Viatris

NCT00821444

COMPLETED Phase 3 11 participants

A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion

Adrian Vella

NCT04459338

COMPLETED NA 11 participants

SpO2 Accuracy of Noninvasive Pulse Oximeter Sensor With Motion Conditions

Stryker Sustainability Solutions

NCT06149416

COMPLETED Phase 1 10 participants

Recovery and Survival of EryDex in Non-patient Volunteers

Quince Therapeutics S.p.A.

NCT02380924

COMPLETED NA 10 participants

Test-retest Reproducibility of [11C]PHNO PET Using the Constant Infusion Paradigm

Yale University

NCT01699607

COMPLETED NA 10 participants

Effects of Surfactants on the Innate Immune System

University of California, San Diego

NCT01951352

COMPLETED Phase 1 10 participants

Temperature Response to a Head-Neck Cooling System

National Institute of Neurological Disorders and Stroke (NINDS)

NCT00025987

COMPLETED NA 10 participants

Swallowing Pressure Profiles in Healthy Adults

University of Florida

NCT03986554

COMPLETED 10 participants

Brain Control of Blinking

National Institute of Neurological Disorders and Stroke (NINDS)

NCT00030199

COMPLETED Phase 4 10 participants

Functional Effects of Botox on the Brain Using MRS and fMRI

University of California, Irvine

NCT03373162

COMPLETED Phase 1 10 participants

Bioavailability of Lesinurad and Intravenous [14C]Lesinurad

Ardea Biosciences

NCT02039700

COMPLETED Phase 1 10 participants

VAS-2 Vasectomy With the Vax-X

University of Washington

NCT00663533

COMPLETED 10 participants

Test of QLS Device to Detect Early Cataracts

National Eye Institute (NEI)

NCT00001617

COMPLETED NA 10 participants

Food Matrix Effect on Flavanol Absorption, Metabolism and Excretion: Methylxanthines

University of California, Davis

NCT03526107

COMPLETED Phase 1 10 participants

To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males

EpiDestiny

NCT05816356

← Previous Page 21 of 22 Next →

Phase Distribution

PhaseTrial count
Phase 1 518
Phase 2 28
Phase 3 11
Phase 4 32

Named interventions

Most-linked intervention names on Healthy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
100 trials
Placebo Other
32 trials
Placebo Dietary supplement
15 trials
Moxifloxacin Drug
9 trials
Midazolam Drug
9 trials
placebo Drug
8 trials
Placebo Biological
7 trials
Omeprazole Drug
6 trials

US sites by state

Facility locations filed on Healthy trials. A trial with sites in several states counts in each.

California 149 trials
Florida 118 trials
Maryland 114 trials
Texas 111 trials
Minnesota 73 trials
Massachusetts 52 trials
Connecticut 49 trials
Pennsylvania 46 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Healthy page

1,096 registered trials, 225 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Healthy condition card totals 1,096 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.